SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2019The new patient - with what & when - Peter Reiss, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2019Novel markers on HBV / HDV co-infection - Valentina Svicher, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2019Specific NS5A polymorphisms correlate with hepatocellular carcinoma in cirrhotic patients infected with HCV genotype 1b - Mohammad AltkhatibView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2019Clinical case- Rocio Montejano Sanchez, MDView Slideset
AMAnne-Geneviève MarcelinMDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2019First line therapies: implications for long term resistance - Anne-Geneviève Marcelin, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2019Presentations from scientists from the industry- Luisa Stamm, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2019Epidemiological study of Doravirine associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy - Anne-Geneviéve MarcelinView Slideset
AKAlina KirichenkoMDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2019High prevalence of the integrase resistance associated accessory mutation L74I in the Russian Federation- Alina KirichenkoView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2019Molecular analysis suggests post-migration HIV-1 acquisition among migrants in Paris, France - Evangelia KostakiView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2019Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study- Barbara RossettiView Slideset
CCCharlotte CharpentierPharmD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2019Seminal HIV-1 RNA and drug concentrations in DTG+3TC dual therapy (ANRS167 Lamidol)- Charlotte CharpentierView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2019First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain - Manuel Reiriz RojasView Slideset
